105 related articles for article (PubMed ID: 16445969)
21. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.
Schorge JO; Drake RD; Lee H; Skates SJ; Rajanbabu R; Miller DS; Kim JH; Cramer DW; Berkowitz RS; Mok SC
Clin Cancer Res; 2004 May; 10(10):3474-8. PubMed ID: 15161704
[TBL] [Abstract][Full Text] [Related]
22. Patients' expectations for follow-up in breast cancer--a preliminary, questionnaire-based study.
Montgomery DA; Krupa K; Wilson C; Cooke TG
Breast; 2008 Aug; 17(4):347-52. PubMed ID: 18455404
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.
Moore LE; Fung ET; McGuire M; Rabkin CC; Molinaro A; Wang Z; Zhang F; Wang J; Yip C; Meng XY; Pfeiffer RM
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1641-6. PubMed ID: 16985025
[TBL] [Abstract][Full Text] [Related]
24. Patient satisfaction with nurse-led telephone follow-up in women with lower urinary tract symptoms.
Jeffery S; Doumouchtsis SK; Fynes M
J Telemed Telecare; 2007; 13(7):369-73. PubMed ID: 17958940
[TBL] [Abstract][Full Text] [Related]
25. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
[TBL] [Abstract][Full Text] [Related]
26. Patient-led breast cancer follow up.
Chapman D; Cox E; Britton PD; Wishart GC
Breast; 2009 Apr; 18(2):100-2. PubMed ID: 19233652
[TBL] [Abstract][Full Text] [Related]
27. Economic impact of prescreening on gastroenterology outpatient clinic practice.
Donnellan F; Harewood GC; Cagney D; Basri F; Patchett SE; Murray FE
J Clin Gastroenterol; 2010 Apr; 44(4):e76-9. PubMed ID: 20305467
[TBL] [Abstract][Full Text] [Related]
28. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract][Full Text] [Related]
29. Optimism, distress, health-related quality of life, and change in cancer antigen 125 among patients with ovarian cancer undergoing chemotherapy.
de Moor JS; de Moor CA; Basen-Engquist K; Kudelka A; Bevers MW; Cohen L
Psychosom Med; 2006; 68(4):555-62. PubMed ID: 16868264
[TBL] [Abstract][Full Text] [Related]
30. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
31. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
32. Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: a community hospital-based intervention study.
Hilarius DL; Kloeg PH; Gundy CM; Aaronson NK
Cancer; 2008 Aug; 113(3):628-37. PubMed ID: 18543317
[TBL] [Abstract][Full Text] [Related]
33. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
34. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
35. Increased mortality in postmenopausal women with serum CA125 elevation.
Jeyarajah AR; Ind TE; MacDonald N; Skates S; Oram DH; Jacobs IJ
Gynecol Oncol; 1999 May; 73(2):242-6. PubMed ID: 10329041
[TBL] [Abstract][Full Text] [Related]
36. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians.
Calhoun EA; Fishman DA; Lurain JR; Welshman EE; Bennett CL
Gynecol Oncol; 2004 Apr; 93(1):164-9. PubMed ID: 15047231
[TBL] [Abstract][Full Text] [Related]
37. Influence exerted on drug prescribing by patients' attitudes and expectations and by doctors' perception of such expectations: a cohort and nested case-control study.
Lado E; Vacariza M; Fernández-González C; Gestal-Otero JJ; Figueiras A
J Eval Clin Pract; 2008 Jun; 14(3):453-9. PubMed ID: 18373568
[TBL] [Abstract][Full Text] [Related]
38. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
39. The role of CA125 in clinical practice.
Moss EL; Hollingworth J; Reynolds TM
J Clin Pathol; 2005 Mar; 58(3):308-12. PubMed ID: 15735166
[TBL] [Abstract][Full Text] [Related]
40. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
